Immunohistochemical evaluation of sentinel lymph nodes in breast carcinoma patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 4, 2002, Pages 296-303

  Cohen, Cynthia ^a,c   Alazraki, Naomi ^a   Styblo, Toncred ^a   Waldrop, Sandra M ^b   Grant, Sandra F ^b   Larsen, Travis ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast carcinoma; Cytokeratins; Immunohistochemistry; Sentinel lymph node

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; STAINING AND LABELING;

EID: 0036901062     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200212000-00002     Document Type: Article

References (98)

1. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391-401.
2. Ku NN. Pathologic examination of sentinel lymph nodes in breast cancer. Surg Oncol Clin North Am 1999;8:469-79.
3. van Diest PJ, Peterse HL, Borgstein PJ, et al. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999;26(suppl): S43-9.
4. Czernieki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999;85: 1098-103.
5. Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-8.
6. Amjadi D, Calvo B, Dressler L, et al. Sentinel lymphadenectomy: immunohistologic validation and improved axillary staging for breast carcinoma: the Chapel Hill experience [Abstract]. Am J Clin Pathol 1999;112:538-9.
7. Moes GS, Guibord RS, Weaver DL, et al. Intraoperative cytologic evaluation of sentinel lymph nodes in breast cancer patients [Abstract]. Mod Pathol 2000;13:28A.
8. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
9. Bass SS, Cox CD, Ku NN, et al. Sensitivity of sentinel lymph node biopsy in detecting metastatic disease in breast cancer patients. Medscape Oncol 2000;3:1-13.
10. Turner RR, Hansen NM, Stern SL, et al. Intraoperative examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Clin 1999;112:627-34.
11. van der Wall E. The sentinel node in breast cancer: implications for adjuvant treatment? Eur J Nucl Med 1999;26(suppl):S17-9.
12. Mathur SC, Czerniak D, Willey S, et al. Pathologic evaluation of sentinel lymph nodes in breast carcinoma [Abstract]. Mod Pathol 2000;13:27A.
13. Delgado Y, Yee H, Wu H, et al. Retrospective evaluation of non-sentinel lymph nodes (NSLN) in breast cancer patients with previously evaluated sentinel lymph nodes (SLN) [Abstract]. Mod Pathol 2000;13:20A.
14. Veronesi U, Paganelli P, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
15. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
16. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: A multicenter validation study. N Engl J Med 1998;339: 941-6.
17. Koller M, Barsuk D, Zippel D, et al. Sentinel lymph node involvement: A predictor for axillary node status with breast cancer: Has the time come? Eur J Surg Oncol 1998;24:166-8.
18. Pfeifer JD. Sentinel lymph node biopsy. Am J Clin Pathol 1999; 112:599-602.
19. Viale G, Renne G, Pruneri G, et al. The axillary lymph node status in breast carcinoma patients with micrometastatic sentinel nodes [Abstract]. Mod Pathol 2000;13:49A.
20. Liu LH, Siziopikou KP, Gabram S, et al. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med 2000;124:1670-3.
21. Altrabulsi B, Ganaraj A, McCarty T, et al. Complete axillary node dissection (CLND) in breast cancer patients with sentinel node (SLN) positive for micrometastases [Abstract]. Mod Pathol 2001; 14:97.
22. Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: A multicenter study. Cancer 2000;88:1099-107.
23. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study. Cancer 1999;86:990-6.
24. Hermanek P, Hutter RVP, Sobin LH, et al. International Union Against Cancer classification of isolated tumor cells and micrometastasis. Cancer 1999, 86:2668-73.
25. Allred DC, Elledge RM. Caution concerning micrometastatic breast carcinoma in sentinel lymph nodes [Editorial]. Cancer 1999. 86:905-7.
26. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222:394-401.
27. 1 carcinoma of the breast. J Am Coll Surg 1996;183:185-9.
28. Ward BS, Burak WE, Wakely PE, et al. Effectiveness of pathologic assessment of sentinel lymph nodes in breast cancer [Abstract]. Mod Pathol 2000;13:49A.
29. Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999;85:2433-8.
30. Krishnamurthy S, Tarco E, Hunt K, et al. Utility of imprint cytology and rapid cytokeratin immunostaining for the intraoperative evaluation of axillary sentinel lymph nodes in breast cancer [Abstract]. Mod Pathol 2001;14:29A.
31. Galimberti V, Zurrida S, Intra M, et al. Sentinel node biopsy interpretation: The Milan experience. Breast J 2000;6:306-9.
32. Massoll N, Henry-Tillman R, Rubio I, et al. Intraoperative touch preparations of axillary sentinel lymph nodes: A rapid, reliable, cost effective, and tissue conserving method [Abstract]. Mod Pathol 2001;14:31A.
33. Lindsey CA, Grimes MM, Powers CN. Decreased accuracy of sentinel node touch imprints in lobular carcinoma [Abstract]. Mod Pathol 2001;14:30A.
34. Ratanawichitrasin A, Biscotti CV, Levy L, et al. Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer. Br J Surg 1999;86: 1346-8.
35. Rubio IT, Korourian S, Cowan C, et al. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 1998;5:689-94.
36. Litz C, Miller R, Ewing G, et al. Intraoperative sentinel lymph node touch imprints are not sensitive in detecting metastatic carcinoma [Abstract]. Mod Pathol 2000;13:26A.
37. van Diest PJ, Torrenga H, Borgstein PJ, et al. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology 1999;35: 14-8.
38. Beach RA, Lawson D, Waldrop SM, et al. Rapid immunohistochemistry (RIHC) for cytokeratin (CK) in the intraoperative evaluation of sentinel lymph nodes (SLNs) in breast cancer patients [Abstract]. Mod Pathol 2001;14:105.
39. Chiu A, DeLellis R, Swistel A, et al. Frozen section examination of axillary sentinel nodes: Is it predictive of status of other axillary nodes [Abstract]. Mod Pathol 2000;13:19A.
40. Reintgen D, Giuliano R, Cox CE. Sentinel node biopsy in breast cancer: an overview. Breast J 2000;6:299-305.
41. Turner RR, Ollila DW, Stern S, et al. Optimal histopathologic examination of the sentinel lymph node in breast carcinoma staging. Am J Surg Pathol 1999;23:263-7.
42. Giuliani AE, Kelemen PR. Sophisticated techniques detect obscure lymph node metastases in carcinoma of the breast. Cancer 1998: 83:391-3.
43. Teng S, Dupont E, McCann C, et al. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg 2000;66: 574-8.
44. Bloom KJ, Anderson J, Assad L, et al. Complete evaluation of sentinel lymph nodes at 0.25 mm intervals utilizing H&E and cytokeratin immunohistochemistry [Abstract]. Mod Pathol 2001; 14:22A.
45. Hsueh EC, Hansen N, Giuliano AE. Intraoperative lymphatic mapping and sentinel lymph node dissection in breast cancer. CA Cancer J Clin 2000;50:279-91.
46. Yared MA, Middleton LP, Ross MI, et al. Recommendation for sentinel lymph node processing in breast cancer [Abstract]. Mod Pathol 2001;14:42A.
47. Schreiber RH, Pendas S, Ku NN, et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 1999;6:95-101.
48. Pendas S, Dauway E, Cox CE, et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65:500-5.
49. Dowlatshahi K, Fan M, Snider HC, et al. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997;80:1188-97.
50. Cote RJ, Petersen HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
51. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;135:1565-8.
52. Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
53. Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
54. Noguchi S, Aihara T, Motamura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC 1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148:649-56.
55. Hoon DS, Sarantou T, Doi F, et al. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int J Cancer 1996; 69:369-74.
56. Fang W, Sahain A, Rajyalakshmi L. Detection of metastasis in axillary sentinel lymph nodes from breast cancer patients with real-time reverse transcription polymerase chain reaction. Am J Clin Pathol 1999;112:539-40.
57. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998;58:4581-4.
58. Bostick PJ, Huynh KT, Sarantou T, et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiplemarker RT-PCR. Int J Cancer 1998;79:645-51.
59. Smith PA, Harlow SP, Krag DN, et al. Submission of lymph node tissue for ancillary studies decreases the accuracy of conventional breast cancer axillary node staging. Mod Pathol 1999;12:781-5.
60. Yaziji H, Gown AM. Detection of pelvic node metastases [Letter]. Am J Clin Pathol 2000;114:149-54.
61. McGuckin MA, Walsh MD, Hohn BG, et al. Occult axillary node metastases in breast cancer: Their detection and prognostic significance. Br J Cancer 1996;73:88-95.
62. Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
63. Chon ZL, Wen DR, Coulsen WF, et al. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991;9:239-48.
64. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447-51.
65. Sedmak DD, Meineke TA, Knechtges DS, et al. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989;2:516-20.
66. Bettelheim R, Price KN, Gelber RD, et al. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
67. de Mascarel I, Bonichan F, Coindre JM, et al. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Re-evaluation with longer follow-up. Br J Cancer 1992;66:523-7.
68. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
69. Nassar IA, Lee AKC, Bosari S, et al. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-7.
70. Kahn HJ, Hanna WM, Chapman JA, et al. Biological significance of micrometastases in histologically negative axillary lymph nodes in breast cancer patients [Abstract]. Mod Pathol 2000;13:24A.
71. de Mascarel I, MacGrogan G, Soubeyran I, et al. Prognostic significance of breast axillary node metastases detected by immunohistochemical stainings (IHM) in 218 patients: Re-evaluation with a longer follow-up and critical analysis [Abstract]. Mod Pathol 2001;14:24A.
72. Rosen PP, Saigo PE, Braun DW, et al. Axillary micro- and macrometastases in breast cancer: Prognostic significance of tumor size. Ann Surg 1981:585-91.
73. Byrne J, Waldron R, McAvinchey D, et al. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987;13:409-11.
74. Pickren JW. Significance of occult metastases: A study of breast cancer. Cancer 1961;14:1266-71.
75. Deshpande CG, Gupta A, Wiley EL, et al. Size of sentinel lymph node metastasis predicts additional axillary lymph node metastasis [Abstract]. Mod Pathol 2001;14:24A.
76. Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720-6.
77. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000;88:2540-5.
78. Treseler P, Rabban J. Clinical significance of micrometastases in breast sentinel lymph nodes [Abstract]. Mod Pathol 2001;14:39A.
79. Zhang YQ, Li Z, Ngadiman S, et al. Micrometastasis in sentinel lymph node: Is there more? [Abstract]. Mod Pathol 2001;14:43A.
80. Viale G, Mazzarol G, Pruneri G, et al. The size of micrometastases in axillary lymph nodes of breast carcinoma patients correlates with the occurrence of additional axillary metastases [Abstract]. Mod Pathol 2001;14:39A.
81. Lee A, Hunt K, Kuerer H, et al. Predictors of non-sentinel lymph node metastasis in breast carcinoma [Abstract]. Mod Pathol 2001; 14:30A.
82. 1 (≤ 2.0 cm) than larger breast cancers [Abstract]. Mod Pathol 2000;13:19A.
83. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
84. Brown MR, Kohn EC, Hutter RVP. The new millennium: Applying novel technology to the study of the cancer cell in situ. Cancer 2000;88:2-5.
85. Yesner R. Axillary sentinel lymph node examination in breast carcinoma [Letter]. Arch Pathol Lab Med 2000;124:189.
86. Scheunemann P, Izbicki JR, Pantel K. Tumorigenic potential of apparently tumor-free lymph nodes [Letter]. N Engl J Med 1999; 340:1687.
87. Janni W, Hepp F, Rjosk D, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92:46-53.
88. Ollila DW, Brennan MB, Giuliano AE. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer. Arch Surg 1998;133: 647-51.
89. Jansen L, Doting MH, Rutgers EJ. et al. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg 2000;87:920-5.
90. Noguchi M, Koyasaki N, Ohta N, et al. Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer. Arch Surg 1993;128:242-6.
91. van der Ent FW, Kengen RA, van der Pol HA, et al. Sentinel node biopsy in 70 unselected patients with breast cancer: Increased feasibility by using 10mCi radiocolloid in combination with a blue dye tracer. Eur J Surg Oncol 1999;25:24-9.
92. Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999;86:2436-46.
93. Holdworth PJ, Hopkinson JM, Leveson SH. Benign axillary epithelial lymph node inclusions: A histological pitfall. Histopathology 1988;13:226-8.
94. Carter BA, Jensen RA, Simpson JF, et al. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000;113:259-65.
95. Linden MD, Zarbo RJ. Which cytokeratin antibody is optimal for detecting metastatic breast carcinoma in sentinel lymph node (SLN) biopsy specimens [Abstract]. Mod Pathol 2000;13:224A.
96. Pelosi G. The use of monoclonal antibody anticytokeratins for detecting lymph node micrometastases from breast carcinoma. Arch Pathol Lab Med 1990;114:450-1.
97. Xu X, Roberts SA, Pasha TL, et al. Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma. Arch Pathol Lab Med 2000;124:1310-3.
98. Zhang Y, Godwin TA. Standardized technical approach to sentinel node analysis in breast carcinoma: Is it possible? [Abstract]. Mod Pathol 2001;14:42A.